BiotechTube

ASP8825

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patients With Impaired Renal Function and Haemodialysis

Conditions

Patients With Impaired Renal Function and Haemodialysis

Trial Timeline

Feb 1, 2008 → Oct 1, 2008

NCT ID
NCT02629224

About ASP8825

ASP8825 is a phase 1 stage product being developed by Astellas Pharma for Patients With Impaired Renal Function and Haemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT02629224. Target conditions include Patients With Impaired Renal Function and Haemodialysis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (3)

NCT IDPhaseStatus
NCT02632331Phase 1Completed
NCT02629224Phase 1Completed
NCT02658188Phase 3Completed

Competing Products

20 competing products in Patients With Impaired Renal Function and Haemodialysis

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
77
R744 + Epoetin betaChugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744Chugai PharmaceuticalPhase 3
77
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
41
FK949EAstellas PharmaPhase 1
33
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
ASP015KAstellas PharmaPhase 1
33
ASP7991Astellas PharmaPhase 1
33
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
77
ATG-FAstellas PharmaApproved
85
CelecoxibAstellas PharmaPre-clinical
23
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 1
33
ASP1585Astellas PharmaPhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85